Shots:

• The P-IIa study assesses the safety & efficacy of ENV-101 (200mg, QD) vs PBO to treat idiopathic pulmonary fibrosis patients (n=41) for 12wks.
• The study showed a 1.9% vs 1.3% mean improvement in ppFVC, a 200mL increase in total lung capacity among 80% of patients vs 56mL decrease in 70% of them, reduced quantitative interstitial lung disease (QILD) by 9.4% vs 1.1% increase, quantitative lung fibrosis (QLF) by 2% vs 0.87% increase & quantitative ground glass (QGG) by 4.6% vs 0.29% increase
• Based on presented data, the company to initiate P-II (WHISTLE-PF) study having a global P-IIb IPF arm & a parallel P-II progressive pulmonary fibrosis (PPF) arm, for which the company has secured $132.5M Series C funding

Ref: Aileron Therapeutics |Image: Aileron Therapeutics

Related News:- Aileron Therapeutics Reports Cohort 1 Results from the P-Ib Study of LTI-03 for Idiopathic Pulmonary Fibrosis (IPF)

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com